{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05951179",
            "orgStudyIdInfo": {
                "id": "TARA-002-101-Ph2"
            },
            "organization": {
                "fullName": "Protara Therapeutics",
                "class": "INDUSTRY"
            },
            "briefTitle": "Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer",
            "officialTitle": "A Phase 2, Open-Label Study to Evaluate the Safety and Anti-Tumor Activity of Intravesical Instillation of TARA-002 in Adults With High-Grade Non-Muscle Invasive Bladder Cancer",
            "acronym": "ADVANCED-2",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "safety-and-efficacy-study-of-intravesical-instillation-of-tara-in-adults-with-high-grade-non-muscle-invasive-bladder-cancer"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-09-15",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2030-05",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2030-08",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-06-29",
            "studyFirstSubmitQcDate": "2023-07-14",
            "studyFirstPostDateStruct": {
                "date": "2023-07-18",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-22",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-24",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Protara Therapeutics",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "TARA-002-101-Ph2 is an open-label study to investigate the safety and anti-tumor activity of intravesical instillation of TARA-002 in adults 18 years of age or older with high-grade CIS NMIBC (\u00b1 Ta/T1).\n\nThe purpose of this Phase 2 study (TARA-002-101-Ph2) is to further assess the safety and anti-tumor activity of TARA-002 at the RP2D which has been established in the Phase 1a dose finding study (TARA-002-101-Ph1a).\n\nThis Phase 2 study includes participants with CIS NMIBC (\u00b1 Ta/T1) with active disease (defined as disease present at last tumor evaluation prior to signing ICF).\n\nParticipants will be enrolled into one of 2 cohorts:\n\nCohort A:\n\n* Participants with CIS (\u00b1 Ta/T1) who are BCG naive, or\n* Participants with CIS (\u00b1 Ta/T1) who are BCG exposed and have not received intravesical BCG for at least 24 months prior to the most recent CIS diagnosis\n\nCohort B:\n\n* Participants with persistent or recurrent CIS (\u00b1 Ta/T1) who are BCG unresponsive within 12 months of completion of adequate BCG therapy (minimum 5/6 doses induction and 2/3 doses maintenance or 2/6 doses reinduction)"
        },
        "conditionsModule": {
            "conditions": [
                "Non-muscle Invasive Bladder Cancer"
            ],
            "keywords": [
                "Non-muscle invasive bladder Cancer",
                "bladder cancer",
                "high grade Ta",
                "high grade NMIBC",
                "carcinoma in situ"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "interventionModelDescription": "All participants will receive 6 weekly instillations of TARA-002 at the established RP2D (First Treatment Period). Participants who are eligible for reinduction after the First Treatment Period will receive 6 additional weekly doses of TARA-002 instillation as part of the Second Treatment Period. Participants confirmed to have a complete response after the First Treatment Period will receive 3 additional weekly doses of TARA-002 instillation as maintenance during the Second Treatment Period. All eligible participants will receive 3 weekly doses of TARA-002 instillation as part of the Third Treatment Period (maintenance) at Months 6, 9, 12, 15, and 18. Following the Third Treatment Period, all participants will continue to the Follow up Period from Month 21 until Month 60.",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 127,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "TARA-002",
                    "type": "EXPERIMENTAL",
                    "description": "TARA-002 is a lyophilized biological preparation for instillation containing cells of Streptococcus pyogenes (Group A, type 3) Su strain treated with benzylpenicillin.",
                    "interventionNames": [
                        "Biological: TARA-002"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "BIOLOGICAL",
                    "name": "TARA-002",
                    "description": "All participants will receive 6 weekly instillations of TARA-002 at the established RP2D (First Treatment Period). Participants who are eligible for reinduction after the First Treatment Period will receive 6 additional weekly doses of TARA-002 instillation as part of the Second Treatment Period. Participants confirmed to have a complete response after the First Treatment Period will receive 3 additional weekly doses of TARA-002 instillation as maintenance during the Second Treatment Period. All eligible participants will receive 3 weekly doses of TARA-002 instillation as part of the Third Treatment Period (maintenance) at Months 6, 9, 12, 15, and 18. Following the Third Treatment Period, all participants will continue to the Follow up Period from Month 21 until Month 60.",
                    "armGroupLabels": [
                        "TARA-002"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Cohort A and B: Incidence of high-grade Complete Response at any time according to central pathology after treatment with TARA-002",
                    "timeFrame": "Month 3 to Month 60"
                },
                {
                    "measure": "Cohort A: Incidence of high-grade Complete Response at any time by subgroup (BCG naive and BCG exposed > 24 months) according to central pathology after treatment with TARA-002",
                    "timeFrame": "Month 3 to Month 60"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Cohort A and B: Duration of high-grade Complete Response rate at Months 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, 48, 54, and 60 after treatment with TARA-002",
                    "timeFrame": "Month 3 to Month 60"
                },
                {
                    "measure": "Cohort A and B: High-grade Complete Response rate at Months 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, 48, 54, and 60 after treatment with TARA-002",
                    "timeFrame": "Month 3 to Month 60"
                },
                {
                    "measure": "Cohort A and B: Duration of Complete Response (all recurrent bladder cancer, including low grade Ta) after treatment with TARA-002",
                    "timeFrame": "Month 3 to Month 60"
                },
                {
                    "measure": "Cohort A and B: Complete Response rate (all recurrent bladder cancer, including low grade Ta) at Months 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, 48, 54, and 60 after treatment with TARA-002",
                    "timeFrame": "Month 3 to Month 60"
                },
                {
                    "measure": "Cohort A and B: Progression free survival after treatment with TARA-002",
                    "timeFrame": "60 months"
                },
                {
                    "measure": "Cohort A and B: Disease-specific progression free survival after treatment with TARA-002",
                    "timeFrame": "60 months"
                },
                {
                    "measure": "Cohort A and B: Overall survival after treatment with TARA-002",
                    "timeFrame": "60 months"
                },
                {
                    "measure": "Cohort A and B: Disease specific survival after treatment with TARA-002",
                    "timeFrame": "60 months"
                },
                {
                    "measure": "Cohort A and B: Time to cystectomy after treatment with TARA-002",
                    "timeFrame": "60 months"
                },
                {
                    "measure": "Cohort A and B: Time to recurrence delayed cystectomy after treatment with TARA-002",
                    "timeFrame": "60 months"
                },
                {
                    "measure": "Cohort A and B: Time to progression after treatment with TARA-002",
                    "timeFrame": "60 months"
                },
                {
                    "measure": "Cohort A and B: Time to disease worsening after treatment with TARA-002",
                    "timeFrame": "60 months"
                },
                {
                    "measure": "Cohort A and B: Incidence and severity of AEs, TEAEs, SAEs and TESAEs after treatment with TARA-002",
                    "description": "AE = adverse event; TEAE = treatment emergent adverse event; SAE = serious adverse event; TESAE = treatment emergent serious adverse event",
                    "timeFrame": "Day 1 to Month 60"
                },
                {
                    "measure": "Cohort A and B: Change from baseline in urine pharmacodynamic biomarker levels (including IL-6, IL-8, IFN-\u03b3, and TNF-\u03b1) after treatment with TARA-002",
                    "timeFrame": "Day 1 to Day 72"
                },
                {
                    "measure": "Cohort A and B: Quality of Life based on the EORTC questionnaire QLQ-NMIBC24",
                    "description": "EORTC = European Organization for Research and Treatment of Cancer; QLQ-NMIBC24 = Questionnaire for Patients with NMIBC",
                    "timeFrame": "Day 1 to Month 24"
                },
                {
                    "measure": "Cohort A and B: Quality of Life based on the EORTC questionnaire QLQ-C30",
                    "description": "EORTC = European Organization for Research and Treatment of Cancer; QLQ-C30 = Questionnaire for Patients with Cancer",
                    "timeFrame": "Day 1 to Month 24"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Male or female participants 18 years of age or older at the time of signing informed consent\n* Participants who have voluntarily given written informed consent after the nature of the study has been explained according to applicable requirements prior to study entry\n* Central histologic confirmation of high-grade non-muscle invasive CIS (\u00b1 Ta/T1) with active disease\n* Participants who are BCG naive, or participants who are BCG exposed and have not received intravesical BCG for at least 24 months prior to the most recent CIS diagnosis (Cohort A). Participants with persistent or recurrent CIS (\u00b1 Ta/T1) who are BCG unresponsive within 12 months of completion of adequate BCG therapy (Cohort B).\n\nExclusion Criteria:\n\n* Penicillin allergy (participants with a questionable history of allergy to penicillin will undergo penicillin blood allergy testing via central laboratory\n* Predominant (defined as \\> 50%) adenocarcinoma, squamous cell carcinoma, or histological variants including plasmacytoid, sarcomatoid, or squamous components according to central review\n* Concomitant prostatic or upper tract urothelial involvement per Investigator's assessment\n* Nodal and metastatic disease are excluded if they existed at any time (whether present or in the past)\n* Any history of \u2265 T2 bladder cancer that existed at any point in time in the participant's history\n\nFor more information on eligibility criteria, please contact the Sponsor",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Chief Scientific Operations Officer",
                    "role": "CONTACT",
                    "phone": "16468440337",
                    "email": "clinicaltrials@protaratx.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Chief Scientific Operations Officer",
                    "affiliation": "Protara Therapeutics",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Urology Group of Southern California",
                    "status": "RECRUITING",
                    "city": "Los Angeles",
                    "state": "California",
                    "zip": "90017",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Use Central Contact",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.05223,
                        "lon": -118.24368
                    }
                },
                {
                    "facility": "Brigham and Women's Hospital",
                    "status": "RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02115",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Use Central Contact",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "AccuMed Research Associates",
                    "status": "RECRUITING",
                    "city": "Garden City",
                    "state": "New York",
                    "zip": "11530",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Use Central Contact",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.72677,
                        "lon": -73.6343
                    }
                },
                {
                    "facility": "University of Rochester, Department of Urology",
                    "status": "RECRUITING",
                    "city": "Rochester",
                    "state": "New York",
                    "zip": "14642",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Use Central Contact",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 43.15478,
                        "lon": -77.61556
                    }
                },
                {
                    "facility": "Carolina Urologic Research Center",
                    "status": "RECRUITING",
                    "city": "Myrtle Beach",
                    "state": "South Carolina",
                    "zip": "29572",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Use Central Contact",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.68906,
                        "lon": -78.88669
                    }
                },
                {
                    "facility": "Urology Associates PC",
                    "status": "RECRUITING",
                    "city": "Nashville",
                    "state": "Tennessee",
                    "zip": "37209",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Use Central Contact",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 36.16589,
                        "lon": -86.78444
                    }
                },
                {
                    "facility": "Urology Austin, LLC",
                    "status": "RECRUITING",
                    "city": "Austin",
                    "state": "Texas",
                    "zip": "78745",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Use Central Contact",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 30.26715,
                        "lon": -97.74306
                    }
                },
                {
                    "facility": "Clinical Trial Network",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77074",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Use Central Contact",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "Virginia Urology",
                    "status": "RECRUITING",
                    "city": "Richmond",
                    "state": "Virginia",
                    "zip": "23235",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Use Central Contact",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.55376,
                        "lon": -77.46026
                    }
                },
                {
                    "facility": "Arensia Kapitanivka - PPDS",
                    "status": "RECRUITING",
                    "city": "Kapitanivka",
                    "zip": "08111",
                    "country": "Ukraine",
                    "contacts": [
                        {
                            "name": "Use Central Contact",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 48.91719,
                        "lon": 31.71671
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000001749",
                    "term": "Urinary Bladder Neoplasms"
                },
                {
                    "id": "D000093284",
                    "term": "Non-Muscle Invasive Bladder Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000014571",
                    "term": "Urologic Neoplasms"
                },
                {
                    "id": "D000014565",
                    "term": "Urogenital Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000052776",
                    "term": "Female Urogenital Diseases"
                },
                {
                    "id": "D000005261",
                    "term": "Female Urogenital Diseases and Pregnancy Complications"
                },
                {
                    "id": "D000091642",
                    "term": "Urogenital Diseases"
                },
                {
                    "id": "D000001745",
                    "term": "Urinary Bladder Diseases"
                },
                {
                    "id": "D000014570",
                    "term": "Urologic Diseases"
                },
                {
                    "id": "D000052801",
                    "term": "Male Urogenital Diseases"
                },
                {
                    "id": "D000002277",
                    "term": "Carcinoma"
                },
                {
                    "id": "D000009375",
                    "term": "Neoplasms, Glandular and Epithelial"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M5030",
                    "name": "Urinary Bladder Neoplasms",
                    "asFound": "Bladder Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5535",
                    "name": "Carcinoma in Situ",
                    "relevance": "LOW"
                },
                {
                    "id": "M2976",
                    "name": "Non-Muscle Invasive Bladder Neoplasms",
                    "asFound": "Non-muscle Invasive Bladder Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M17320",
                    "name": "Urologic Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M17315",
                    "name": "Urogenital Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M2875",
                    "name": "Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27093",
                    "name": "Female Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14127",
                    "name": "Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M8399",
                    "name": "Female Urogenital Diseases and Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M5026",
                    "name": "Urinary Bladder Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M17319",
                    "name": "Urologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27095",
                    "name": "Male Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M12320",
                    "name": "Neoplasms, Glandular and Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M13311",
                    "name": "Penicillin G",
                    "relevance": "LOW"
                },
                {
                    "id": "M13312",
                    "name": "Penicillin G Benzathine",
                    "relevance": "LOW"
                },
                {
                    "id": "M13313",
                    "name": "Penicillin G Procaine",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}